PDF(Pubmed)
Abstract：
UNASSIGNED: Currently, the bipolar radiofrequency ablation forceps manufactured by AtriCure are the main instrument for surgical ablation in patients with rheumatic heart disease (RHD) concomitant with atrial fibrillation (AF). The bipolar radiofrequency ablation forceps by Med-Zenith has a greater advantage in price compared with AtriCure. However, few studies have been reported on the comparison of their clinical efficacy. The aim of this study is to compare the short-term clinical efficacy of the two ablation forceps for RHD concomitant with AF.
UNASSIGNED: Clinical data of 167 patients with RHD concomitant with AF admitted to the Department of Cardiac Major Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, were retrospectively analyzed, and the restoration efficacy of sinus rhythm (SR) and cardiac function after surgery were compared with two ablation forceps.
UNASSIGNED: The end-systolic diameter of the right atrium and the end-systolic diameter of the left atrium in the patients of both groups at each postoperative time point decreased compared with that of the preoperative period (P < 0.05), and the left ventricular ejection fraction started to improve significantly at 6 months after surgery compared with that of the preoperative period (P < 0.05). There was no difference between the two groups of patients in the comparison of the aforementioned indicators at different points in time (P > 0.05). At 12 months postoperatively, the SR maintenance rate in using the ablation forceps by Med-Zenith (73.3%) was lower than that for AtriCure (86.4%) and the cumulative recurrence rate of AF in using the Med-Zenith ablation forceps was greater than that for AtriCure.
UNASSIGNED: The two bipolar radiofrequency ablation forceps compared in the study are safe and effective in treating patients of RHD concomitant with AF, and the ablation forceps by AtriCure may be more effective in restoring SR in the short term.
UNASSIGNED: Clinical data of 167 patients with RHD concomitant with AF admitted to the Department of Cardiac Major Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, were retrospectively analyzed, and the restoration efficacy of sinus rhythm (SR) and cardiac function after surgery were compared with two ablation forceps.
UNASSIGNED: The end-systolic diameter of the right atrium and the end-systolic diameter of the left atrium in the patients of both groups at each postoperative time point decreased compared with that of the preoperative period (P < 0.05), and the left ventricular ejection fraction started to improve significantly at 6 months after surgery compared with that of the preoperative period (P < 0.05). There was no difference between the two groups of patients in the comparison of the aforementioned indicators at different points in time (P > 0.05). At 12 months postoperatively, the SR maintenance rate in using the ablation forceps by Med-Zenith (73.3%) was lower than that for AtriCure (86.4%) and the cumulative recurrence rate of AF in using the Med-Zenith ablation forceps was greater than that for AtriCure.
UNASSIGNED: The two bipolar radiofrequency ablation forceps compared in the study are safe and effective in treating patients of RHD concomitant with AF, and the ablation forceps by AtriCure may be more effective in restoring SR in the short term.
摘要：
■目前，AtriCure制造的双极射频消融钳是风湿性心脏病(RHD)合并心房颤动(AF)患者手术消融的主要器械.与AtriCure相比，Med-Zenith双极射频消融钳在价格上具有更大的优势。然而,很少有研究报道它们的临床疗效比较。本研究的目的是比较两种消融钳治疗RHD合并AF的短期临床疗效。
■入住心脏大血管外科的167例RHD合并房颤患者的临床资料，川北医学院附属医院,进行了回顾性分析，比较两种消融钳对窦性心律(SR)及术后心功能的恢复效果。
■两组患者术后各时间点右心房收缩末期内径和左心房收缩末期内径均较术前下降(P<0.05),术后6个月左心室射血分数较术前明显改善(P<0.05)。两组患者在不同时间点的上述指标比较差异无统计学意义(P>0.05)。术后12个月，Med-Zenith消融钳的SR维持率(73.3%)低于AtriCure(86.4%),Med-Zenith消融钳的房颤累积复发率高于AtriCure。
■本研究中比较的两种双极射频消融钳在治疗伴有房颤的RHD患者方面是安全有效的，AtriCure的消融钳可能在短期内更有效地恢复SR。
■入住心脏大血管外科的167例RHD合并房颤患者的临床资料，川北医学院附属医院,进行了回顾性分析，比较两种消融钳对窦性心律(SR)及术后心功能的恢复效果。
■两组患者术后各时间点右心房收缩末期内径和左心房收缩末期内径均较术前下降(P<0.05),术后6个月左心室射血分数较术前明显改善(P<0.05)。两组患者在不同时间点的上述指标比较差异无统计学意义(P>0.05)。术后12个月，Med-Zenith消融钳的SR维持率(73.3%)低于AtriCure(86.4%),Med-Zenith消融钳的房颤累积复发率高于AtriCure。
■本研究中比较的两种双极射频消融钳在治疗伴有房颤的RHD患者方面是安全有效的，AtriCure的消融钳可能在短期内更有效地恢复SR。
